This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Draghi, D. C. Articles by Sahm, D. F. Search for Related Content PubMed PubMed Citation Articles by Draghi, D. C. Articles by Sahm, D. F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2005, p. 5024-5032, Vol. 49, No. 12
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.12.5024-5032.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

In Vitro Activity of Linezolid against Key Gram-Positive Organisms Isolated in the United States: Results of the LEADER 2004 Surveillance Program

Focus Bio-Inova, Inc., Herndon, Virginia,¹ Pfizer Inc., Pfizer Global Pharmaceuticals, New York, New York²

Received 27 April 2005/ Returned for modification 6 July 2005/ Accepted 26 September 2005

Since the approval of linezolid in 2000, sporadic reports of resistance have been given and a greater understanding of the underlying mechanisms of resistance has been gained. However, since these developments, an updated status of the in vitro activity of linezolid against gram-positive organisms from the United States has not been reported. The LEADER 2004 surveillance initiative was undertaken to obtain current and representative data on the activity of linezolid against key species, including isolates with significant resistance phenotypes. Organisms were isolated during 2004 and included 2,872 Staphylococcus aureus, 496 coagulase-negative staphylococcus (CNS), 428 Enterococcus faecalis, 196 Enterococcus faecium, and 422 Streptococcus pneumoniae isolates. All S. aureus isolates (54.2% oxacillin resistant) were susceptible to linezolid (MIC₉₀ = 2 µg/ml); MIC distributions were consistent, regardless of oxacillin or multidrug resistance status. For CNS, one nonsusceptible isolate was encountered (Staphylococcus epidermidis; MIC = 32 µg/ml), but overall, the MIC₉₀ (1 µg/ml) was lower than that obtained with S. aureus. For E. faecalis and E. faecium, 99.5% and 96.4% of isolates, respectively, were linezolid susceptible. Both species had an MIC₉₀ of 2 µg/ml, and MIC distributions did not vary with the vancomycin susceptibility status of the populations analyzed. Linezolid nonsusceptibility was not encountered among the S. pneumoniae isolates. These findings indicate that linezolid nonsusceptibility has remained rare among staphylococci and uncommon and sporadic among enterococci. Nonetheless, careful and ongoing monitoring of the in vitro effectiveness of linezolid will be needed so that any changes to the current status may be detected as soon as possible.

This article has been cited by other articles:

• Draghi, D. C., Benton, B. M., Krause, K. M., Thornsberry, C., Pillar, C., Sahm, D. F. (2008). In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. J Antimicrob Chemother 62: 116-121 [Abstract] [Full Text]  
• Draghi, D. C., Benton, B. M., Krause, K. M., Thornsberry, C., Pillar, C., Sahm, D. F. (2008). Comparative Surveillance Study of Telavancin Activity against Recently Collected Gram-Positive Clinical Isolates from across the United States. Antimicrob. Agents Chemother. 52: 2383-2388 [Abstract] [Full Text]  
• Kelly, S., Collins, J., Maguire, M., Gowing, C., Flanagan, M., Donnelly, M., Murphy, P. G. (2008). An outbreak of colonization with linezolid-resistant Staphylococcus epidermidis in an intensive therapy unit. J Antimicrob Chemother 61: 901-907 [Abstract] [Full Text]  
• Slover, C. M, Rodvold, K. A, Danziger, L. H (2007). Tigecycline: A Novel Broad-Spectrum Antimicrobial. The Annals of Pharmacotherapy 41: 965-972 [Abstract] [Full Text]  
• Jones, R. N., Stilwell, M. G., Hogan, P. A., Sheehan, D. J. (2007). Activity of Linezolid against 3,251 Strains of Uncommonly Isolated Gram-Positive Organisms: Report from the SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother. 51: 1491-1493 [Abstract] [Full Text]  
• Dobbs, T. E., Patel, M., Waites, K. B., Moser, S. A., Stamm, A. M., Hoesley, C. J. (2006). Nosocomial Spread of Enterococcus faecium Resistant to Vancomycin and Linezolid in a Tertiary Care Medical Center.. J. Clin. Microbiol. 44: 3368-3370 [Abstract] [Full Text]